Literature DB >> 25343109

Idiopathic pulmonary fibrosis: The current status of its epidemiology, diagnosis, and treatment in China.

Haibo Huang1, Xiaonu Peng1, Chongwen Zhong1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a type of intractable and rare disease, and its epidemiology in China is still unclear. The diagnosis and treatment of IPF has received considerable attention and two editions of guidelines on IPF diagnosis and treatment have been published by the Chinese Society of Respiratory Diseases. Treatment of IPF with Traditional Chinese Medicine (TCM) has been widely investigated in China and several types of TCM extracts are reported to be effective in animal models. One effective treatment is lung transplantation; this treatment has been successfully performed in China, yielding satisfactory long-term survival.

Entities:  

Keywords:  Prevalence; Traditional Chinese Medicine; guideline; lung transplantation; therapy

Year:  2013        PMID： 25343109      PMCID： PMC4204549          DOI： 10.5582/irdr.2013.v2.3.88

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN： 2186-3644


  24 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Idiopathic pulmonary fibrosis--results from a Japanese nationwide epidemiological survey using individual clinical records.

Authors:  Shoji Ohno; Takakiyo Nakaya; Masashi Bando; Yukihiko Sugiyama
Journal:  Respirology       Date:  2008-07-24       Impact factor: 6.424

3.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

4.  [Smoking and passive smoking in Chinese, 2002].

Authors:  Gong-huan Yang; Jie-min Ma; Na Liu; Ling-ni Zhou
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2005-02

5.  Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis.

Authors:  R Hubbard; S Lewis; K Richards; I Johnston; J Britton
Journal:  Lancet       Date:  1996-02-03       Impact factor: 79.321

6.  Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure.

Authors:  K Iwai; T Mori; N Yamada; M Yamaguchi; Y Hosoda
Journal:  Am J Respir Crit Care Med       Date:  1994-09       Impact factor: 21.405

7.  Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK.

Authors:  J Gribbin; R B Hubbard; I Le Jeune; C J P Smith; J West; L J Tata
Journal:  Thorax       Date:  2006-07-14       Impact factor: 9.139

8.  Unilateral lung transplantation for pulmonary fibrosis.

Authors: 
Journal:  N Engl J Med       Date:  1986-05-01       Impact factor: 91.245

9.  Epidemiology of cryptogenic fibrosing alveolitis in Moravia and Silesia.

Authors:  V Kolek
Journal:  Acta Univ Palacki Olomuc Fac Med       Date:  1994

10.  Protective roles of Cordyceps on lung fibrosis in cellular and rat models.

Authors:  Mengli Chen; Florence W K Cheung; Ming Hung Chan; Pak Kwan Hui; Siu-Po Ip; Yick Hin Ling; Chun-Tao Che; Wing Keung Liu
Journal:  J Ethnopharmacol       Date:  2012-07-13       Impact factor: 4.360
View more
  8 in total

1.  Radix Astragali and Radix Angelicae Sinensis in the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-analysis.

Authors:  Yufeng Zhang; Lina Gu; Qingqing Xia; Lijun Tian; Jia Qi; Mengshu Cao
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

Review 2.  Chinese Herbal Medicines Compared with N-Acetylcysteine for the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review of Randomized Controlled Trials.

Authors:  Jing Guo; Bin Li; Wenbin Wu; Zhichao Wang; Fei Wang; Taipin Guo
Journal:  Evid Based Complement Alternat Med       Date:  2019-06-13       Impact factor: 2.629

3.  Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis.

Authors:  Kun Ji; Jianling Ma; Liangmin Wang; Niuniu Li; Shangjuan Dong; Liqing Shi
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-12       Impact factor: 2.629

4.  Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer.

Authors:  Guang Yang; Jun Xing; Batuer Aikemu; Jing Sun; Minhua Zheng
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

5.  Danggui Buxue Decoction Ameliorates Idiopathic Pulmonary Fibrosis through MicroRNA and Messenger RNA Regulatory Network.

Authors:  Huizhe Zhang; Xue Wang; Yanchen Shi; Mengying Liu; Qingqing Xia; Weilong Jiang; Yufeng Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-26       Impact factor: 2.650

6.  Combination of Salvia miltiorrhiza and ligustrazine attenuates bleomycin-induced pulmonary fibrosis in rats via modulating TNF-α and TGF-β.

Authors:  Chengliang Huang; Xu Wu; Shengpeng Wang; Wenjun Wang; Fang Guo; Yuanyuan Chen; Bi Pan; Ming Zhang; Xianming Fan
Journal:  Chin Med       Date:  2018-07-04       Impact factor: 5.455

7.  Chinese herbal medicines compared with N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: Protocol for a systematic review.

Authors:  Jing Guo; Bin Li; Wenyuan Li; Yi Pan; Zhichao Wang; Yuxiao Wu; Fei Wang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

8.  The Influence of BuqiHuoxueTongluo Formula on Histopathology and Pulmonary Function Test in Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Rats.

Authors:  Xiaolin Yu; Yanxia Zhang; Xiaohua Yang; Xiaomei Zhang; Xinxiang Wang; Xuemei Liu; Yan Yan
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-26       Impact factor: 2.629
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.